- Home
- OGEN vs NLSP Comparison
OGEN vs NLSP Comparison
Compare OGEN & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OGEN
- NLSP
- Stock Information
- Founded
- OGEN 1996
- NLSP 2015
- Country
- OGEN United States
- NLSP Switzerland
- Employees
- OGEN N/A
- NLSP N/A
- Industry
- OGEN Biotechnology: Pharmaceutical Preparations
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- OGEN Health Care
- NLSP Health Care
- Exchange
- OGEN Nasdaq
- NLSP Nasdaq
- Market Cap
- OGEN 2.5M
- NLSP 12.4M
- IPO Year
- OGEN N/A
- NLSP 2021
- Fundamental
- Price
- OGEN $1.50
- NLSP $2.50
- Analyst Decision
- OGEN
- NLSP
- Analyst Count
- OGEN 0
- NLSP 0
- Target Price
- OGEN N/A
- NLSP N/A
- AVG Volume (30 Days)
- OGEN 1.1M
- NLSP 411.8K
- Earning Date
- OGEN 08-08-2025
- NLSP 07-15-2025
- Dividend Yield
- OGEN N/A
- NLSP N/A
- EPS Growth
- OGEN N/A
- NLSP N/A
- EPS
- OGEN N/A
- NLSP N/A
- Revenue
- OGEN N/A
- NLSP N/A
- Revenue This Year
- OGEN N/A
- NLSP N/A
- Revenue Next Year
- OGEN N/A
- NLSP N/A
- P/E Ratio
- OGEN N/A
- NLSP N/A
- Revenue Growth
- OGEN N/A
- NLSP N/A
- 52 Week Low
- OGEN $1.35
- NLSP $1.30
- 52 Week High
- OGEN $75.60
- NLSP $15.59
- Technical
- Relative Strength Index (RSI)
- OGEN 27.35
- NLSP 52.64
- Support Level
- OGEN $1.35
- NLSP $2.16
- Resistance Level
- OGEN $4.19
- NLSP $3.08
- Average True Range (ATR)
- OGEN 0.43
- NLSP 0.24
- MACD
- OGEN -0.22
- NLSP -0.00
- Stochastic Oscillator
- OGEN 5.14
- NLSP 30.21
About OGEN Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.